Novo Nordisk and devices firm Abbott have announced a partnership that aims to make diabetes management easier by linking technologies such as continuous glucose monitoring with connected i
The US regulator has approved Novo Nordisk’s long-acting therapy for haemophilia A, Esperoct, as the Danish pharma seeks to maintain its presence in an increasingly competitive sector of th
Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US.
Novo Nordisk is set to file its daily semaglutide type 2 diabetes pill after it cleared a phase 3 trial assessing its cardiac safety, with results showing it also reduced risk of cardiovasc
BioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression helps patients, as it develops an experimental cure for th